Covid-19 patients who are getting an experimental drug called remdesivir have been recovering quickly,
with most going home in days, STAT News reported Thursday after it obtained a video of a conversation about the trial.
The patients taking part in a clinical trial of the drug have all had severe respiratory symptoms and fever,
but were able to leave the hospital after less than a week of treatment, STAT quoted the doctor leading the trial as saying.
"The best news is that most of our patients have already been discharged, which is great.
We've only had two patients perish,"
Dr. Kathleen Mullane,
an infectious disease specialist at the University of Chicago
who is leading the clinical trial, said.
"Such a test may help scientists learn how widespread the infection is,
and how long people remain immune after recovering.
new test, by contrast, looks for protective antibodies in a finger prick of blood.
It tells doctors whether a patient has ever been exposed to the virus and now may have some immunity.
That is important for several reasons. People with immunity might be able to venture safely from their homes and help shore up the work force.
It may be particularly important for doctors and nurses to know whether they have antibodies."
"Food and Drug Administration approved one of the drugs for clinical trials,
as New York becomes the epicenter for the pandemic in the U.S.
During a Sunday press briefing, Cuomo said
750,000 doses of chloroquine,
70,000 doses of hydroxychloroquine and
10,000 doses of Zithromax were acquired by New York state for the trial.
Chloroquine (an anti-malaria drug) and hydroxychloroquine (used for lupus and arthritis)
were approved by the FDA for clinical trials as possible coronavirus treatments,
while Zithromax is a brand-name antibiotic"
"Moderna Inc. of Cambridge, Massachusetts, has already begun Phase I human testing
of its mRNA-1273 at Kaiser Permanente Washington Health Research Institute in Seattle.
The test has enrolled 45 healthy adults ages 18 to 55. Phase I will continue over the next six weeks.
The vaccine was developed using part of the genetic sequence from COVID-19 called mRNA, or messenger RNA.
Traditional vaccines use the virus itself; Moderna's mRNA-1273 works off a sequence of the virus' genetic code, instead.
The vaccine is designed to direct the body's cells to produce an antibody — a virus-fighting protein — and spur a robust immune response. It has already shown promise in tests on animals.
Phase I of testing looks at the vaccine's safety and whether it is producing an immune response.
A later phase of research will look at whether the vaccine is effective in preventing infection.
Subjects get an injection on days 1 and 29 and will be followed for 12 months after the second injection.
Regeneron Pharmaceuticals of Tarrytown, New York, is working on an antibody treatment that uses the virus itself.
The company genetically modifies mice to have human immune systems and
then exposes them to part of the virus. The mice then build up antibodies to fight the virus.
Scientists have isolated the antibodies, as well as antibodies from humans who have recovered from COVID-19, and
they will select the top two antibodies to create a cocktail that is injected in the patient.
The two antibodies will target different parts of the virus and may help protect against multiple viral variants.
In theory, that means the drug could still be effective if the virus mutates.
Regeneron's drug could be used as a treatment for those who are already infected,
but according to the company it could also be used as
a preventive measure for the healthy, like a vaccine.
Such drugs are sometimes referred to as "passive" vaccines.
Inovio Pharmaceuticals of Plymouth Meeting, Pennsylvania,
is using an approach similar to Moderna's to develop a vaccine by modeling off the virus' sequence.
Three hours after China published the sequence of the virus online, Inovio developed INO-4800.
Inovio uses something called DNA medicine, which is made up of optimized DNA plasmids.
These are small circles of double-stranded DNA that are reorganized by a computer-sequencing technology and
designed to produce a specific immune response in the body.
Inovio delivers the optimized plasmids directly into the cells,
where they begin replicating and strengthening the body's natural response mechanisms"
the first approved coronavirus drug in China
The National Medical Products Administration of China has approved the use of Favilavir,
an anti-viral drug, as a treatment for coronavirus.
The drug has reportedly shown efficacy in treating the disease with
minimal side effects in a clinical trial involving 70 patients.
The clinical trial is being conducted in Shenzhen, Guangdong province"
An ebola drug developed by Gilead Sciences
that was found to be ineffective is now being tested in two phase III randomised clinical trials in Asian countries.
The trials are being performed on 761 patients in a randomised, placebo-controlled, double-blind study at
multiple hospitals in Wuhan, the epicentre of the novel coronavirus outbreak.
The results from the trials are expected to be available over the next few weeks.
According to a report by The New England Journal of Medicine (NEJM),
remdesivir, when administered to a coronavirus patient in the US, appeared to have improved the clinical condition.
The University of Nebraska Medical Center is also carrying out clinical trials to test the safety and efficacy of the drug.
The first patient to be administered the drug is an evacuee from the Diamond Princess cruise ship.
by Roche to treat coronavirus-related complications
China approved the use of Roche’s Actemra for the treatment of severe complications related to coronavirus.
Drugs like Actemra have the ability to prevent cytokine storms or overreaction of the immune system,
which is considered as the main reason behind organ failure leading to death in some coronavirus patients.
Actemra is also being evaluated in a clinical trial in China, which is expected to enroll 188 coronavirus patients.
The clinical trial is expected to be conducted until May 10.
"Sixty-four children and teens in New York State are suspected of having a mysterious inflammatory syndrome that is
believed to be linked to COVID-19, the New York Department of Health said in an alert issued Wednesday.
A growing number of similar cases — including at least one death — have been reported in other parts of the U.S. and Europe,
though the phenomenon is still not well-understood.
Pediatricians say parents should not panic; the condition remains extremely rare.
But researchers also are taking a close look at this emerging syndrome, and say
parents should be on the lookout for symptoms in their kids that might warrant a quick call to the doctor —
a persistent high fever over several days and significant abdominal pains with repeated vomiting,
after which the child does not feel better."
"Faced with an increased risk of blood clots, patients with the coronavirus may benefit from blood thinning medications.
Blood thinners may help keep COVID-19 patients on ventilators alive longer, a study published Wednesday suggests.
In recent weeks, physicians have noticed that the sickest coronavirus patients are more prone to forming blood clots —
an unexpected symptom for a respiratory virus."
The CDC has long said said that fever, cough and shortness of breath are indications that
someone might have the disease caused by the novel coronavirus.
It has now added six more conditions that may come with the disease:
repeated shaking with chills,
sore throat and
new loss of taste or smell.
The symptoms usually appear within two to 14 days after exposure to the virus, the CDC says.
It stresses the "emergency warning signs" for COVID-19 are
persistent pain or pressure in the chest,
confusion or inability to arouse. and
bluish lips or face.
People with any of these symptoms should seek medical attention immediately, the CDC says."
"Coronavirus symptoms may include skin problems, such as rashes and so-called "COVID toes," experts believe.
One small study in Italy found 20 percent of COVID-19 patients had skin problems,
while anecdotal evidence from other countries indicates a link between dermatological problems and the virus.
Patients developed skin complaints when their COVID-19 symptoms started, and 10 after they were hospitalized.
14 patients had a red rash,
three had hives, and
one had chickenpox-like blisters.
The torso was the most affected area, the team said, and the lesions usually healed in a few days.
These issues did not seem to correspond to how sick the patients were, according to the letter"
"Doctors sound alarm about patients in their 30s and 40s left debilitated or dead.
Some didn’t even know they were infected.
Reports of strokes in the young and middle-aged — not just at Mount Sinai,
but also in many other hospitals in communities hit hard by the novel coronavirus —
are the latest twist in our evolving understanding of the disease it causes.
The numbers of those affected are small but nonetheless remarkable
because they challenge how doctors understand the virus"
"People with coronavirus infections may be most contagious
one to two days before they start to feel ill, new research suggests.
What’s more, considering pairs of people
in which one person definitely caught the coronavirus from the other,
scientists estimate that about 44 percent of COVID-19 cases
may spread from person to person before symptoms appear"
"A recent study by Bhatraju and others found that the patients' lungs appeared to deteriorate quickly.
The crash typically happens seven days into the disease and can occur in young, otherwise healthy victims of COVID-19.
Now doctors and researchers are increasingly convinced that, in some cases at least,
the cause is the body's own immune system overreacting to the virus.
The problem, known broadly as a "cytokine storm,"
can happen when the immune system triggers a runaway response that
causes more damage to its own cells than to the invader it's trying to fight"
"The coronavirus can spread about one to three days before symptom
start, a top medical official of the World Health Organization said.
Whether the person is symptomatic or presymptomatic,
the disease is still spread in the same way — through droplets from the nose and mouth,
said the official, Dr. Maria Van Kerkhove,
the WHO’s team lead on the coronavirus"
"Many patients who've either tested positive for the coronavirus, or have been told by their physicians to assume they have it,
also develop a headache and sore throat.
Others become sick to their stomach with nausea or diarrhea.
Some patients say they have no interest in eating.
Many report they're losing their senses of taste and smell, the British Rhinological Society said recently.
Just this week, a small study published in JAMA Ophthalmology added another potential COVID-19 warning sign:
pink eye, also known as conjunctivitis.
A third of the 38 patients in the report had the inflammatory eye condition.
But it's also becoming more clear that some
infected people spreading the virus don't have any symptoms at all."
American Academy of Ophthalmology: https://www.aao.org/headline/alert-important-coronavirus-context
But for her and her colleagues at the Life Care Center and admitting doctors at a nearby hospital,
the eyes became a sign that coronavirus had struck, she told CNN.
"We've had patients that just had the red eyes as the only symptom that we saw and
go to the hospital and pass away," she said.
"I've even had the disaster medical control physician say,
'Do they have the red eyes?' And I will say yes.
And he'll say, 'I'll find you a bed.' It's just something about this,
the way that it affects these patients."
American Academy of Otolaryngology:
Because it attacks the lungs,
the coronavirus that causes COVID-19 could be an especially serious threat to those
who smoke tobacco or marijuana or who vape.
People with opioid use disorder (OUD) and methamphetamine use disorder may also be vulnerable
due to those drugs’ effects on respiratory and pulmonary health.
Additionally, individuals with a substance use disorder are more likely to experience homelessness or
incarceration than those in the general population, and
these circumstances pose unique challenges regarding transmission of the virus that causes COVID-19
New C.D.C. data shows that nearly 40% of patients sick enough to be hospitalized
were age 20 to 54.
But the risk of dying was significantly higher in older people.
Of the 508 patients known to have been hospitalized,
38 percent were notably younger — between 20 and 54.
And nearly half of the 121 patients who were admitted to intensive care units
were adults under 65, the C.D.C. reported.
“I think everyone should be paying attention to this,”